Ruxolitinib
Composition
The formulation Contains ruxolitinib as the active ingredient.
Indications
Treatment of chronic idiopathic myelofibrosis and Polycythemia vera
Side effects
Headache, Dizziness, Low blood platelets, Anemia (low number of red blood cells), Infection, Fatigue, Decreased white blood cell count (neutrophils), Increased alanine aminotransferase, Bruising
Precautions
Use with caution in patients with a history of infections or liver dysfunction. Monitor blood counts and liver function regularly.
Contraindications
Contraindicated in patients with known hypersensitivity to ruxolitinib or any component of the formulation.
Dosage and administration
Dose based on platelet count, typically 5-20 mg twice daily
Countries
Canada, Australia, EU countries
Available Forms
Tablets
Manufacturing Services
Third Party Manufacturing Company WHO, GMP, EUGMP, USFDA, In India | Contract Manufacturing Organization (CMO) WHO, GMP, EUGMP, USFDA Services in India, Mumbai, Navi Mumbai| Contract Development and Manufacturing Organization (CDMO) WHO, GMP, EUGMP, USFDA - Services in India | Pharmaceutical Contract Manufacturing Company WHO, GMP, EUGMP, USFDA in Navi Mumbai, India | Top Pharmaceutical Product Exporters, Suppliers, Distributer WHO, GMP, EUGMP, USFDA in Mumbai